Immunotherapy side effect may be reversible: thyroid drug taper trial launches
NCT ID NCT07421869
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This study looks at whether hypothyroidism caused by immune checkpoint inhibitors (a type of cancer immunotherapy) can go away after stopping the immunotherapy. 107 adult cancer patients who developed hypothyroidism during treatment and are now off immunotherapy will gradually reduce their thyroid medication (levothyroxine) every 3 months. The goal is to see how many can stop the medication completely and for how long.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Levothyroxine tapering
What this could lead to
If successful, this could show that some patients can safely stop thyroid medication after finishing immunotherapy, reducing lifelong drug burden.
What could go wrong
This is a small, early-phase study without a control group. Many patients may still need lifelong thyroid hormone, and the tapering process could cause temporary symptoms.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HYPOTHYROIDISM are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Department of Internal Medicine, Seoul National University Bundang Hospital
RECRUITINGSeongnam-si, South Korea
Contact Phone: •••-•••-•••• Email: •••••@•••••